Optimata Ltd. announced today that the US Patent and Trademark Office has granted patent approval for the use of Optimata's Virtual Patient biosimulation technology in the optimization of drug treatments for cancer patients. This is the first approval of a series of patent applications filed by Optimata for the company's platform technology, which employs mathematical modeling to optimize the use of drugs in the development of new drugs and in the treatment of diseases.
The approved patent is titled "System and Methods for Optimized Drug Delivery and Progression of Diseased and Normal Cells" and is registered as patent number 6,871,171.
"The awarding of this patent, which covers the company's core Virtual Patient technology, reinforces Optimata's position as the leading developer of innovative biosimulation solutions aimed at dramatically accelerating drug development. We have already successfully used this technology in our collaborations with pharmaceutical and biotech companies," said Guy Malchi, Optimata's president.
Optimata's technology is based on a computer-generated method of accurately predicting how individual patients or patient populations will respond to a compound. The technology combines computer models of human physiology, specific diseases and the therapeutic impact of a compound. The technology forecasts the results of putative preclinical and clinical experiments at an unprecedented scale, allowing an unlimited number of "virtual trials" to be carried out on a wide range of dosages, treatment schedules and patient population characteristics.
In this way it is possible to overcome the time and cost limitations of the trial-and-error methods currently used in drug development and to establish the optimal therapy protocol in a significantly quicker way.
Optimata is currently completing a clinical trial to predict breast cancer therapy outcomes for cancer drugs such as Adriamycin, Docetaxel, Paclitaxel, Vinorelbine and Tamoxifen at Nottingham City Hospital in the UK and at
the Soroka Medical Center in Israel.
About Optimata
Optimata is the developer of the Optimata Virtual Patient system biology technologies for use in drug development and in the individualization of therapeutic treatments. Located in Ramat Gan, Israel, Optimata was founded by Prof. Zvia Agur, a world-renowned biomathematician who has pioneered methods of using computer modeling for optimizing treatment protocols in cancer and pathogenic diseases.
